Fredun Pharma's Credit Rating Bolstered to IVR BBB+ on Stronger Financials

Fredun Pharmaceuticals' total bank facilities valued at ₹156.17 crore have seen their long-term credit rating upgraded to IVR BBB+ (Stable) by Infomerics.
This rating hike follows robust operational performance and a stronger financial profile observed in FY24-FY25.

Reader Takeaway: Rating upgraded on stronger financials; lingering governance concerns remain a watchpoint.

What just happened (today’s filing)

Infomerics has upgraded Fredun Pharmaceuticals Limited's credit rating for its long-term bank facilities from IVR BBB (Stable) to IVR BBB+ (Stable).

This upgrade encompasses a total of ₹156.17 crore in bank facilities, comprising ₹143.17 crore for long-term use and ₹13.00 crore for working capital.

The rating agency cited improved operational performance, a stronger financial profile, and disciplined capital management during the audited financial years FY24 and FY25 as key drivers for the revision.

The rating for short-term bank facilities has been reaffirmed at IVR A2.

Why this matters

The enhanced credit rating is expected to significantly improve Fredun Pharmaceuticals' financial flexibility.

It should also bolster the company's institutional credibility, potentially leading to more favourable borrowing costs and better access to capital for future growth initiatives.

The backstory (grounded)

Fredun Pharmaceuticals, established in 1987, is a diversified pharmaceutical player involved in manufacturing formulations, supplements, and healthcare products, with a notable export presence. [4, 6].

Historically, the company's credit ratings have acknowledged promoter experience and a growing topline, but have also flagged constraints such as an elongated working capital cycle and vulnerability to regulatory changes. [3, 10, 12].

Infomerics had previously rated the company's long-term facilities at IVR BBB-/Stable, and a CRISIL rating was at BB+/Stable. [7, 14].

The company has been actively launching new products and segments, contributing to its growth trajectory. [9, 15].

What changes now

• Increased confidence from banking partners and financial institutions.
• Enhanced ability to secure funding for expansion plans.
• Potential for a reduction in borrowing costs.
• Improved standing for accessing future capital requirements.

Risks to watch

Fredun Pharmaceuticals faces a notable risk stemming from a SEBI Adjudication Order received on July 1, 2025. [11, 15]. This order cited alleged violations related to financial statement preparation, auditor reporting, corporate governance certifications, and audit committee quorum issues.

While no monetary penalty was imposed, these compliance lapses highlight past governance shortcomings that warrant investor attention.

Furthermore, forward-looking statements are inherently subject to general risks, including government actions, economic developments, and technological shifts, which could impact actual results. [9].

Historically, an elongated working capital cycle and price volatility of raw materials have also been identified as pressures. [10, 12].

Peer comparison

Fredun Pharma's new IVR BBB+ (Stable) rating places it in a solid investment-grade category. However, larger peers often command higher ratings. For instance, Mankind Pharma Limited, a dominant player in the Indian market, holds a strong [ICRA]AA+(Stable) rating. Calyx Chemicals And Pharmaceuticals Limited has a BBB- (Stable) rating from Acuité, and CPL Pharmaceuticals is rated IND A- (Stable) by India Ratings, suggesting varied credit strengths within the sector. [19, 20, 17].

Context metrics (time-bound)

• Total bank facilities rated stand at ₹156.17 crore, assessed for FY24-FY25 performance.
• Consolidated Total Revenues for FY25 were ₹456 crore.
• Consolidated EBITDA for FY25 was ₹55 crore.
• Consolidated Profit After Tax (PAT) for FY25 was ₹21 crore.

What to track next

• Future financial performance of Fredun Pharmaceuticals, particularly its ability to sustain revenue growth and manage costs.
• The impact of new product segments on overall profitability.
• How the company addresses the governance concerns raised by the SEBI Adjudication Order.
• Any changes or reaffirmations in its credit ratings from Infomerics and other agencies.
• Developments related to its working capital management and debt utilization.